Evidence map›Paper›PMID 36495032›Full record

ArticleThe International journal of artificial organs2023

CoronaVac, BNT162b2 and heterologous COVID-19 vaccine outcomes in patients with ventricular assist device.

Mehmet Karahan, Umit Kervan, Sinan Sabit Kocabeyoglu, Dogan Emre Sert, Yasemin Tezer Tekce, Omer Abdullah Yavuz, Seref Alp Kucuker, Mehmet Ali Ozatik, Zeki Catav, Erol Sener

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The International journal of artificial organs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mehmet KarahanCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.ORCID 0000-0003-1705-4999
Umit KervanCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.ORCID 0000-0001-7198-069X
Sinan Sabit KocabeyogluCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Dogan Emre SertCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Yasemin Tezer TekceInfectious Diseases, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Omer Abdullah YavuzCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Seref Alp KucukerCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Mehmet Ali OzatikCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Zeki CatavCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Erol SenerCardiovascular Surgery, Ankara City Hospital, Cankaya, Ankara, Turkiye.
Memorial Ankara Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA consensus has not yet been reached regarding which COVID-19 vaccine program should be applied in patients with ventricular assist device (VAD). Our aim was to assess the clinical outcome of inactivated, mRNA and heterologous vaccine program in patient with VAD.

methodsIn this retrospective and cross-sectional study; adult patients who underwent VAD implantation between January 2012 and September 2021 and received any vaccine that were used in Republic of Türkiye for COVID-19, were included. The patients were divided into three groups according to the type of vaccine; "inactivated," "mRNA" and "heterologous." Clinical outcomes were analyzed.

resultsEighteen patients were in each group in the "inactivated," "mRNA" and "heterologous" groups. Mean age was 51.6 ± 12 years in "inactivated" group, 42.5 ± 15.5 years in "mRNA" group and 41.1 ± 15.4 years in "heterologous" group. There was no significant difference between the groups in age, gender, body surface area, body mass index and etiology (

conclusionAll vaccine that used for COVID-19 are safe and effective in patients with VAD. In countries that give priority to inactivated vaccines, mRNA vaccines may then be made as boosters.

Indexed as

COVID-19Heart-Assist DevicesAdultBNT162 VaccineCOVID-19 VaccinesCross-Sectional StudiesHumansMiddle AgedRetrospective StudiesVaccines, InactivatedBNT162 VaccineCOVID-19 Vaccinessinovac COVID-19 vaccineVaccines, InactivatedCOVID-19vaccineventricular assist device

Identifiers

PMID36495032
PMCPMC9747367
OpenAlexW4312080539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.